|Bid||34.45 x 900|
|Ask||34.66 x 1000|
|Day's Range||31.29 - 35.63|
|52 Week Range||6.83 - 54.84|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.60|
CAMBRIDGE, Mass., Oct. 05, 2018 -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will participate in a question and answer format presentation at the.
CAMBRIDGE, Mass., Oct. 01, 2018-- Solid Biosciences Inc. today announced that management will present at the Cell & Gene Meeting on the Mesa on Wednesday, October 3, 2018 at 3:30 pm PT in La Jolla, California.. ...
Solid Biosciences (SLDB) is focused on developing products that treat Duchenne muscular dystrophy (or DMD), a genetic muscle-wasting disease caused by mutations in the dystrophin gene. Solid Biosciences’ SGT-001 is being developed to restore functional dystrophin protein expression in patients’ muscles. The drug has received rare pediatric disease designation in the United States and orphan drug designation in the United States and the European Union.
Solid Biosciences (SLDB) incurred a net loss of $17.98 million in the second quarter of 2018, which compares to a net loss of $11.31 million in the second quarter of 2017, translating to a net loss per share of $0.52 in the second quarter of 2018. Its net loss per share was $0.66 in the second quarter of 2017. The decrease in net loss per share was due to an increase in the company’s outstanding shares, which increased from 17.04 million in the second quarter of 2017 to 34.45 million in the second quarter of 2018.
Stocks focused on gene therapy have garnered strong investor interest in 2018. While some of them have been climbing steadily, others have received strong price corrections on pipeline news. In this series, we’ll analyze four companies: BioMarin Pharmaceutical (BMRN), Solid Biosciences (SLDB), Spark Therapeutics (ONCE), and uniQure (QURE).
Solid Biosciences Inc. (SLDB) today announced that Sukumar Nagendran, M.D., has been elected to its Board of Directors. Dr. Nagendran brings to Solid more than 30 years of experience in key functional areas, including gene therapy development, clinical strategy, medical affairs and diagnostics. “Dr. Nagendran is an accomplished physician, drug developer and biotech executive, with deep and relevant experience in gene therapy development and proven results,” said Ilan Ganot, Chief Executive Officer, Co-Founder and President of Solid Biosciences.
The Street has a lot of faith in Sarepta Therapeutics, Inc. (NASDAQ: SRPT ). The biotech firm notched its 20th bullish rating Thursday to further neutralize a lone Hold. The Rating Credit Suisse analysts ...
Scholar Rock Holding Corp. (srrk) shares dropped 11% in active Thursday trade after Pfizer Inc. (pfe) announced it plans to stop two ongoing clinical trials for a similar rare-disease drug. "Although SRRK has not formally announced its strategy in DMD, we see the setting as ideal for lead candidate SRK-015, which could complement the gene therapies that are in development from Sarepta (srpt) Solid Bio (sldb) and Pfizer...Neither SRPT and SLDB have anti-myostatin programs of their own," he said, adding that SRK-015 "should be more selective and provide an improved therapeutic window relative to programs like doma which target mature myostatin." Phase 1 safety data for the therapy could be available before the end of the year, providing a catalyst for Scholar Rock shares, according to Nierengarten.
-IGNITE DMD Phase I/II Clinical Trial Patient Screening Has Resumed-. CAMBRIDGE, Mass., Aug. 10, 2018-- Solid Biosciences Inc. today reported financial results for the second quarter ended June 30, 2018 ...
A manufacturing-related hold on Sarepta Therapeutics Inc (NASDAQ: SRPT )’s Duchenne muscular dystrophy candidate catalyzed a recent sell-off. Morgan Stanley sees a buying opportunity in the otherwise-lauded ...
Sarepta Therapeutics Inc (NASDAQ: SRPT ) announced a manufacturing-related hold Wednesday on its Phase 1/2 trial of microdystrophin gene therapy for Duchenne muscular dystrophy. Solid Biosciences Inc (NASDAQ: ...
Today, resTORbio (TORC) is trading at $13.36, which represents ~48.28% growth compared to yesterday. On July 24, resTORbio stock closed at $9.01, which represents ~19% growth from its 52-week low of $7.54 on April 10. TORC hit its 52-week high of $21.09 on February 26. Today, resTORbio announced positive results from its Phase 2b trial of RTB101 to evaluate the safety and efficacy of the drug in older individuals who are at high risk of morbidity and mortality due to respiratory tract infections.
The first half of 2018 brought Dropbox Inc (NASDAQ: DBX ), Spotify Technology SA (NYSE: SPOT ) and 118 other market newbies raising an aggregate $35.2 billion — the most since 2014. Bettors on the young ...
The Street grew more bullish on Solid Biosciences Inc (NASDAQ: SLDB ) last week following progress announcements on Solid and peer candidates. At least three analysts raised their valuation targets: The ...
Investor focus is on the DMD segment this week with Sarepta presenting encouraging gene therapy study data and the FDA lifting its clinical hold on Solid Biosciences' gene therapy study.
Solid Biosciences plunged Wednesday on high volume after rival Sarepta Therapeutics reported strong data for its Duchenne muscular dystrophy treatment.
On June 19, Solid Biosciences’ (SLDB) stock price rose ~46.6% to $43.00. On June 19, Solid Biosciences’ stock price hit a 52-week high of $54.84.
The biotech sector showed volatility with a few companies gaining on positive data readouts while a few plunging on dismal results.
NEW YORK, NY / ACCESSWIRE / June 20, 2018 / Shares of Foundation Medicine exploded on Tuesday after announcing that it has entered into a definitive merger agreement for Roche to acquire the outstanding shares of FMI`s common stock not already owned by Roche and its affiliates at a price of US$ 137.00 per share. Shares of Solid Biosciences also broke out after announcing that the FDA has lifted a clinical hold on the company's phase I/II trial, IGNITE DMD, for its experimental candidate, SGT-001. Foundation Medicine, Inc. shares closed up 28.46% on Tuesday, with about 6.3 million shares traded compared to an average trading volume of about 409,00 shares.